FNCH Finch Therapeutics Group, Inc.

Overview and Growth

In fiscal 2023, Finch Therapeutics Group, Inc. recorded $107.00K of revenue, net loss of $74.75M, and an operating cash outflow of $31.50M. The $107.00K revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. The top line contracted 87.6% from $861.00K in fiscal 2022; this top-line contraction left the company with a smaller revenue base. On a per-share basis, diluted EPS was -$46.59, which connects the reported earnings outcome with the company’s diluted share count. Diluted shares averaged 1.60M; this is the reported share base over which the company’s diluted per-share earnings were spread. Diluted shares moved 0.9% from 1.59M in fiscal 2022, leaving the current share base higher year over year. Total assets stood at $55.37M, showing the scale of resources supporting revenue, earnings, liquidity, and financing. The revenue-to-assets relationship was 0.0x, showing the sales generated relative to the resources carried on the balance sheet.

Profitability

The company recorded an operating loss of $83.86M after the reported operating expense base. The company ended the period with a net loss of $74.75M, extending the operating result through all remaining items. EBITDA was negative $82.36M, showing a deficit before interest, taxes, depreciation, and amortization. Before income taxes, the company recorded a loss of $78.22M, bridging the operating result to the final net loss. The reported tax benefit was $3.46M, favorably bridging the pretax and after-tax results. Relative to period-end equity, the net loss represented 326.6%. The net loss equaled 135.0% of period-end assets, showing the deficit relative to the asset base. The bottom-line deficit decreased from $114.65M in fiscal 2022 to $74.75M.

Liquidity and Capital Structure

At period end, the $55.37M asset base was financed through $32.49M of liabilities and $22.89M of equity. Current assets were $25.85M against $4.08M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. At 6.33x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. The company held $25.12M in cash and equivalents, a narrower liquidity measure than total current assets. The cash balance equaled 615.2% of current liabilities, showing how much near-term coverage came from cash alone. The company carried $0.00 of total debt at period end, which frames its leverage and debt-service burden. The debt-to-equity relationship was 0.0x, showing how much debt the company carried for each unit of book equity. Debt represented 0.0% of total assets, placing borrowing in the context of the company’s full resource base. Book equity represented 41.3% of total assets, quantifying the balance-sheet share supported by shareholder capital. Liabilities represented 58.7% of total assets, quantifying the liability-funded share of the company’s resource base. Cash and equivalents equaled 45.4% of total assets, showing the liquid cash component within the company’s broader resource base. The asset base changed 66.0% from $162.94M in fiscal 2022, leaving current total assets lower year over year. Against $95.71M of equity in fiscal 2022, the current book-equity balance moved 76.1% and ended lower. The reported cash balance changed 64.6% from $71.04M in fiscal 2022, ending lower year over year.

Cash Flow and Earnings Quality

Operating activities used $31.50M of cash, resulting in an operating cash outflow for the year. Negative free cash flow was $31.50M, leaving a cash deficit after capital spending and reducing financial flexibility. Relative to total assets, the post-investment cash deficit measured 56.9%. The operating cash outflow narrowed to $31.50M from $74.85M in fiscal 2022.

Based on the annual report for the fiscal year ending Dec 31, 2023. Analysis generated Oct 21, 2026.